Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience-Reference-Cited by-同舟云学术

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Published:2019-01-06 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Mamlouk Omar,Selamet Umut,Machado Shana,Abdelrahim Maen,Glass William F.,Tchakarov Amanda,Gaber Lillian,Lahoti Amit,Workeneh Biruh,Chen Sheldon,Lin Jamie,Abdel-Wahab Noha,Tayar Jean,Lu Huifang,Suarez-Almazor Maria,Tannir Nizar,Yee Cassian,Diab Adi,Abudayyeh Ala

Funder

Foundation for the National Institutes of Health

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0478-8.pdf

Reference28 articles.

1. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.

2. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.

3. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377:1919–29.